Miniature type V-F CRISPR-Cas nucleases enable targeted DNA modification in cells

Prior research has shown that Class 2 CRISPR systems rely on a single effector protein containing a conserved RuvC-like nuclease domain. These proteins vary significantly in size, ranging from over one thousand amino acids to smaller variants. Compact RNA-guided nucleases are highly desirable for in vivo genome editing applications to simplify cellular delivery. That uncertainty drove the investigation into whether smaller variants could function effectively within complex eukaryotic environments. While miniature Cas12f effectors were known to cleave double-stranded DNA in vitro, their efficacy in living cells remained unproven. No prior work had resolved the functional capacity of these proteins for targeted modifications in human or plant systems. This gap motivated the current characterization of specific miniature type V-F nucleases. Researchers sought to determine if these compact systems could overcome existing delivery limitations for therapeutic and agricultural genetic engineering.

The aim of this study is to biochemically characterize two miniature type V-F CRISPR-Cas nucleases, specifically SpCas12f1 and AsCas12f1. Researchers sought to address the challenge of delivering large gene-editing proteins into eukaryotic cells. The team investigated whether these compact effectors could successfully perform targeted DNA modifications. This effort was motivated by the need for smaller tools to simplify cellular delivery approaches for genome engineering. The study explores the functional potential of these proteins, which range from 422 to 497 amino acids in size. By testing these nucleases in both human and plant cells, the authors aimed to demonstrate their utility in diverse biological systems. The motivation stems from the desire to overcome the size limitations inherent in traditional CRISPR-Cas9 or Cas12a systems. This research provides a critical assessment of whether miniature variants can effectively serve as alternatives for advanced genetic modification tasks.

The review approach involved biochemical characterization of two specific miniature type V-F nucleases, SpCas12f1 and AsCas12f1. Researchers assessed the functional capacity of these proteins to cleave double-stranded DNA in controlled laboratory settings. Following initial validation, the team transitioned to testing these effectors within human and plant cell lines. The study design focused on evaluating the efficacy of these compact proteins for targeted DNA modification. Investigators employed specific delivery techniques to introduce the nucleases into the target eukaryotic systems. To optimize performance in plants, the team applied short heat pulses during the experimental procedure. This methodology allowed for a direct comparison of the editing outcomes between the two variants. The systematic evaluation provided insights into the potential of these miniature systems for practical genetic engineering applications.

Key findings from the literature reveal that SpCas12f1 successfully functions in both human and plant cells to generate targeted modifications. The researchers identified SpCas12f1 as having 497 amino acids and AsCas12f1 as having 422 amino acids. The study confirms that these miniature effectors are capable of performing genetic alterations despite their significantly reduced size. Data show that the editing outcomes in plant cells are notably enhanced when the samples undergo short heat pulses. The investigation demonstrates that these compact nucleases overcome previous barriers to editing in eukaryotic environments. These results establish that the miniature type V-F systems possess the necessary activity for precise DNA manipulation. The findings highlight the functional versatility of these proteins across different biological kingdoms. This evidence supports the potential for utilizing such small effectors in diverse genome engineering workflows.

The authors demonstrate that SpCas12f1 functions effectively to produce targeted modifications in both human and plant cells. This synthesis suggests that miniature type V-F nucleases represent a viable alternative to larger, traditional CRISPR-Cas systems. The researchers propose that the compact nature of these effectors will streamline future cellular delivery strategies. Their findings indicate that short heat pulses can enhance the editing outcomes observed in plant tissues. These results provide a foundation for the continued development of miniature Cas12f1-based genome editing tools. The study confirms that these small proteins are capable of performing precise genetic alterations in eukaryotic organisms. This work implies that size reduction does not preclude the functional utility of CRISPR-associated nucleases. The authors conclude that these specific nucleases offer a promising path forward for expanding the toolkit available for genome engineering.